Behind the CheckMate-77T Trial of a Nivolumab-Based Regimen in NSCLC

Tina Cascone, MD, PhD, assistant professor, in the Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses background of the phase 3 CheckMate-77T trial (NCT04025879) where investigators are assessing the perioperative regimen of neoadjuvant nivolumab (Opdivo) plus chemotherapy followed by surgery and adjuvant nivolumab for the treatment of patients with stage IIA to IIIB non-small cell lung cancer (NSCLC).

Cascone presented updated findings from the study at the 2023 ESMO Congress and shared that these results “support a perioperative nivolumab as a potential new treatment option for our patients with resectable non-small cell lung cancer”.

Transcription:

0:09 | I had the pleasure and the honor to present the results of Checkmate-77T. This is a phase 3 study comparing neoadjuvant nivolumab plus chemotherapy with the adjuvant placebo plus chemotherapy, followed by surgery and adjuvant nivolumab or placebo for previously untreated resectable stage II/IIIB non-small cell lung cancer. The rationale for the study stems from the evidence that nivolumab plus chemo is the standard of care neoadjuvant treatment for eligible patients with resectable non-small cell lung cancer, having demonstrated improvements in [event-free survival] and the pCR as compared with chemo in the CheckMate-816 study. So, a perioperative treatment approach including adjuvant nivolumab could potentially further reduce the risk of disease relapse and improve clinical benefit in our patients with resectable non-small cell lung cancer.

1:04 | So with this in mind, CheckMate-77T is a global, randomized, double-blind, phase 3 study evaluating neoadjuvant nivolumab plus chemotherapy, followed by surgery and adjuvant nivolumab vs neoadjuvant chemo plus nivolumab followed by surgery and adjuvant placebo in patients with unresectable stage II/IIIB non-small cell lung cancer. At this Congress, I presented the results from the pre-specified [progression-free survival] interim analysis along with secondary outcomes and key exploratory analysis.